Entero Therapeutics, Inc.
ENTO
$0.3554
$0.0020.57%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 37.22% | 61.30% | 60.91% | 62.39% | -10.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.14% | 33.54% | 228.95% | 184.49% | 24.39% |
| Operating Income | 0.14% | -33.54% | -228.95% | -184.49% | -24.39% |
| Income Before Tax | -0.11% | -19.38% | -157.91% | -131.63% | -7.97% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.11% | 48.25% | -22.90% | 32.15% | -7.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.34% | 36.72% | -37.18% | 32.15% | -7.97% |
| EBIT | 0.14% | -33.54% | -228.95% | -184.49% | -24.39% |
| EBITDA | 0.05% | -33.42% | -229.51% | -185.16% | -24.45% |
| EPS Basic | 94.75% | 94.24% | -105.80% | -116.32% | -126.27% |
| Normalized Basic EPS | 92.02% | 87.58% | -107.20% | -117.13% | -123.79% |
| EPS Diluted | 91.66% | 91.87% | -106.99% | -117.55% | -126.71% |
| Normalized Diluted EPS | 97.36% | 92.21% | -105.73% | -116.01% | -124.16% |
| Average Basic Shares Outstanding | 768.53% | 1,187.93% | 1,340.29% | 1,120.68% | 930.16% |
| Average Diluted Shares Outstanding | 1,688.01% | 2,936.83% | 4,858.54% | 6,244.09% | 928.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |